Cargando…
Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
SIMPLE SUMMARY: The development of immune checkpoint inhibitors (ICIs) has greatly changed the treatment landscape of multiple malignancies. However, the wide administration of ICIs is mainly obstructed by the low response rate and several life-threatening adverse events. Thus, there is an urgent ne...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750062/ https://www.ncbi.nlm.nih.gov/pubmed/35008273 http://dx.doi.org/10.3390/cancers14010109 |
_version_ | 1784631375205236736 |
---|---|
author | Yang, Fang Wang, Jacqueline F. Wang, Yucai Liu, Baorui Molina, Julian R. |
author_facet | Yang, Fang Wang, Jacqueline F. Wang, Yucai Liu, Baorui Molina, Julian R. |
author_sort | Yang, Fang |
collection | PubMed |
description | SIMPLE SUMMARY: The development of immune checkpoint inhibitors (ICIs) has greatly changed the treatment landscape of multiple malignancies. However, the wide administration of ICIs is mainly obstructed by the low response rate and several life-threatening adverse events. Thus, there is an urgent need to identify sets of biomarkers to predict which patients will respond to ICIs. In this review, we discuss the recently investigated molecular and clinical determinants of ICI response, from the aspects of tumor features, clinical features, as well as tumor microenvironment. ABSTRACT: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) have dramatically changed the landscape of cancer therapy. Both remarkable and durable responses have been observed in patients with melanoma, non-small-cell lung cancer (NSCLC), and other malignancies. However, the PD-1/PD-L1 blockade has demonstrated meaningful clinical responses and benefits in only a subset of patients. In addition, several severe and life-threatening adverse events were observed in these patients. Therefore, the identification of predictive biomarkers is urgently needed to select patients who are more likely to benefit from ICI therapy. PD-L1 expression level is the most commonly used biomarker in clinical practice for PD-1/PD-L1 inhibitors. However, negative PD-L1 expression cannot reliably exclude a response to a PD-1/PD-L1 blockade. Other factors, such as tumor microenvironment and other tumor genomic signatures, appear to impact the response to ICIs. In this review, we examine emerging data for novel biomarkers that may have a predictive value for optimizing the benefit from anti-PD-1/PD-L1 immunotherapy. |
format | Online Article Text |
id | pubmed-8750062 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87500622022-01-12 Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges Yang, Fang Wang, Jacqueline F. Wang, Yucai Liu, Baorui Molina, Julian R. Cancers (Basel) Review SIMPLE SUMMARY: The development of immune checkpoint inhibitors (ICIs) has greatly changed the treatment landscape of multiple malignancies. However, the wide administration of ICIs is mainly obstructed by the low response rate and several life-threatening adverse events. Thus, there is an urgent need to identify sets of biomarkers to predict which patients will respond to ICIs. In this review, we discuss the recently investigated molecular and clinical determinants of ICI response, from the aspects of tumor features, clinical features, as well as tumor microenvironment. ABSTRACT: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) have dramatically changed the landscape of cancer therapy. Both remarkable and durable responses have been observed in patients with melanoma, non-small-cell lung cancer (NSCLC), and other malignancies. However, the PD-1/PD-L1 blockade has demonstrated meaningful clinical responses and benefits in only a subset of patients. In addition, several severe and life-threatening adverse events were observed in these patients. Therefore, the identification of predictive biomarkers is urgently needed to select patients who are more likely to benefit from ICI therapy. PD-L1 expression level is the most commonly used biomarker in clinical practice for PD-1/PD-L1 inhibitors. However, negative PD-L1 expression cannot reliably exclude a response to a PD-1/PD-L1 blockade. Other factors, such as tumor microenvironment and other tumor genomic signatures, appear to impact the response to ICIs. In this review, we examine emerging data for novel biomarkers that may have a predictive value for optimizing the benefit from anti-PD-1/PD-L1 immunotherapy. MDPI 2021-12-27 /pmc/articles/PMC8750062/ /pubmed/35008273 http://dx.doi.org/10.3390/cancers14010109 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Yang, Fang Wang, Jacqueline F. Wang, Yucai Liu, Baorui Molina, Julian R. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges |
title | Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges |
title_full | Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges |
title_fullStr | Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges |
title_full_unstemmed | Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges |
title_short | Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges |
title_sort | comparative analysis of predictive biomarkers for pd-1/pd-l1 inhibitors in cancers: developments and challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750062/ https://www.ncbi.nlm.nih.gov/pubmed/35008273 http://dx.doi.org/10.3390/cancers14010109 |
work_keys_str_mv | AT yangfang comparativeanalysisofpredictivebiomarkersforpd1pdl1inhibitorsincancersdevelopmentsandchallenges AT wangjacquelinef comparativeanalysisofpredictivebiomarkersforpd1pdl1inhibitorsincancersdevelopmentsandchallenges AT wangyucai comparativeanalysisofpredictivebiomarkersforpd1pdl1inhibitorsincancersdevelopmentsandchallenges AT liubaorui comparativeanalysisofpredictivebiomarkersforpd1pdl1inhibitorsincancersdevelopmentsandchallenges AT molinajulianr comparativeanalysisofpredictivebiomarkersforpd1pdl1inhibitorsincancersdevelopmentsandchallenges |